Health & Biotech
ASX Health Stocks: On FDA Monday Mesoblast has lifesaving evidence; Lumos hits a roadblock
Health & Biotech
Weed Week: Greens push hard to legalise cannabis and Cronos has 3% of Aussie GPs on its platform already
Health & Biotech
ASX Health Stocks: New dawn for Alzheimer’s after Biogen’s landmark results; Cogstate soars by proxy
Health & Biotech
Osteopore secures funding to chase world-first 3D printable implant for accelerated bone regeneration
Health & Biotech
Osteopore’s products will be included in Australia’s Prostheses List in November
Health & Biotech
Opyl tips revenue growth from partnership with Consentic and its newly launched screening services
Health & Biotech
New dawn: how an organic sunscreen pioneered a world-leading COVID-killer
Health & Biotech
ASX Health Stocks: Race to develop RNA-based therapies is well and truly on, as these two biotechs add new programs
Health & Biotech
Nutritional Growth Solutions just signed a deal with the world’s largest retailer
Health & Biotech
ASX Health Stocks: Botanix seeks nod from US FDA; PainChek goes big in Japan
Health & Biotech
Biotechnology investing for the social good – making money and a difference
Health & Biotech
Prescient unveils latest big hitter CellPryme-A at prestigious Boston CAR-TCR meeting
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.